## WHAT IS CLAIMED IS:

1. A pharmaceutical composition suitable for oral administration to a human, comprising:

from about 0.5% to about 60% by weight of a pharmaceutically acceptable salt of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid;

- (ii) from about 10% to about 95% by weight of a non-reducing sugar selected from the group consisting of mannitol, xylitol, sorbitol, inositol, sucrose and trehalose;
- (iii) from about 2% to about 60% by weight of a binder selected from the group consisting of microcrystalline cellulose, hydroxypropyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose and polyvinylpyrrolidone;
- (iv) from about 0.5% to about 15% by weight of a disintegrant selected from the group consisting of starch, modified starch, croscarmellose sodium, crospovidone and sodium starch glycolate; and
- (v) from about 0.1% to about 7% by weight of a lubricant selected from the group consisting of calcium stearate, magnesium stearate, stearic acid, tale, hydrogenated vegetable oil and sodium stearyl fumarate.
- 2. The pharmaceutical composition of claim 1, wherein said composition is in the form of a tablet.
- 3. The pharmaceutical composition according to claim 1, comprising:
- (i) from about 0.5% to about 60% by weight of a pharmaceutically acceptable salt of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid;
  - (ii) from about 30% to about 95% by weight of mannitol;
- (iii) from about 2% to about 40% by weight of hydroxypropyl methyl cellulose;

- (iv) from about 1% to about 15% by weight of sodium starch glycolate; and
- (v) from about 0.25% to about 7% by weight of sodium stearyl fumarate.
  - 4. The pharmaceutical composition according to claim 1, comprising:
- (i) from about 10% to about 60% by weight of a pharmaceutically acceptable salt of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid;
  - (ii) from about 10% to about 50% by weight of mannitol;
- (iii) from about 20% to about 60% by weight of microcrystalline cellulose;
- (iv) from about 0.5% to about 10% by weight of croscarmellose sodium; and
  - (v) from about 0.1% to about 3% by weight of magnesium stearate.
- 5. The pharmaceutical composition according to claim 1, wherein said a pharmaceutically acceptable salt of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid is 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium salt trihydrate.
- 6. The pharmaceutical composition according to claim 1, wherein said a pharmaceutically acceptable salt of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid is anhydrous 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium salt.
  - 7. The pharmaceutical composition according to claim 1, comprising:
- (i) from about 0.5% to about 50% by weight of a pharmaceutically acceptable salt of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid;

- (ii) from about 20% to about 90% by weight of a non-reducing sugar selected from the group consisting of mannitol, xylitol, sorbitol, inositol, sucrose and trehalose;
- (iii) from about 5% to about 50% by weight of a binder selected from the group consisting of microcrystalline cellulose, hydroxypropyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose and polyvinylpyrrolidone;
- (iv) from about 0.5% to about 10% by weight of a disintegrant selected from the group consisting of starch, modified starch, croscarmellose sodium, crospovidone and sodium starch glycolate; and
- (v) from about 0.25% to about 5% by weight of a lubricant selected from the group consisting of calcium stearate, magnesium stearate, stearic acid, talc, hydrogenated vegetable oil and sodium stearyl fumarate.
- 8. The pharmaceutical composition of claim 7, wherein said composition is in the form of a tablet.
- 9. The pharmaceutical composition according to claim 7, comprising:
- (i) from about 0.5% to about 50% by weight of a pharmaceutically acceptable salt of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid;
  - (ii) from about 40% to about 90% by weight of mannitol;
- (iii) from about 5% to about 30% by weight of hydroxypropyl methyl cellulose;
- (iv) from about 1% to about 10% by weight of sodium starch glycolate; and
- (v) from about 0.5% to about 5% by weight of sodium stearyl fumarate.

- 10. The pharmaceutical composition according to claim 7, comprising:
- (i) from about 15% to about 40% by weight of a pharmaceutically acceptable salt of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid;
  - (ii) from about 20% to about 40% by weight of mannitol;
- (iii) from about 30% to about 50% by weight of microcrystalline cellulose;
- (iv) from about 0.5% to about 5% by weight of croscarmellose sodium; and
  - (v) from about 0.25% to about 2% by weight of magnesium stearate.
- 11. The pharmaceutical composition according to claim 7, wherein said a pharmaceutically acceptable salt of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid is 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium salt trihydrate.
- 12. The pharmaceutical composition according to claim 7, wherein said a pharmaceutically acceptable salt of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid is anhydrous 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium salt.
  - 13. The pharmaceutical composition according to claim 7, comprising:
- (i) from about 1% to about 30% by weight of a pharmaceutically acceptable salt of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid;
- (ii) from about 30% to about 80% by weight of a non-reducing sugar selected from the group consisting of mannitol, xylitol, sorbitol, inositol, sucrose and trehalose;
- (iii) from about 10% to about 45% by weight of a binder selected from the group consisting of microcrystalline cellulose, hydroxypropyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose and polyvinylpyrrolidone;

- (iv) from about 0.5% to about 8% by weight of a disintegrant selected from the group consisting of starch, modified starch, croscarmellose sodium, crospovidone and sodium starch glycolate; and
- (v) from about 0.5% to about 3% by weight of a lubricant selected from the group consisting of calcium stearate, magnesium stearate, stearic acid, talc, hydrogenated vegetable oil and sodium stearyl fumarate.
- 14. The pharmaceutical composition of claim 13, wherein said composition is in the form of a tablet.
- 15. The pharmaceutical composition according to claim 13, comprising:
- (i) from about 1% to about 30% by weight of a pharmaceutically acceptable salt of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid;
  - (ii) from about 50% to about 80% by weight of mannitol;
- (iii) from about 10% to about 20% by weight of hydroxypropyl methyl cellulose;
- (iv) from about 2% to about 8% by weight of sodium starch glycolate; and
  - (v) from about 1% to about 3% by weight of sodium stearyl fumarate.
- 16. The pharmaceutical composition according to claim 13, comprising:
- (i) from about 20% to about 30% by weight of a pharmaceutically acceptable salt of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid;
  - (ii) from about 25% to about 35% by weight of mannitol;
- (iii) from about 35% to about 45% by weight of microcrystalline cellulose;

. ....

- (iv) from about 0.5% to about 1.5% by weight of croscarmellose sodium; and
  - (v) from about 0.5% to about 1% by weight of magnesium stearate.
- 17. The pharmaceutical composition according to claim 13, wherein said a pharmaceutically acceptable salt of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid is 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium salt trihydrate.
- 18. The pharmaceutical composition according to claim 13, wherein said a pharmaceutically acceptable salt of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid is anhydrous 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium salt.
- 19. The pharmaceutical composition according to claim 15, comprising:
- (i) from about 3% to about 26% by weight of a pharmaceutically acceptable salt of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid;
  - (ii) from about 53% to about 76% by weight of mannitol;
- (iii) about 13% to about 15% by weight of hydroxypropyl methyl cellulose;
  - (iv) about 4% to about 6% by weight of sodium starch glycolate; and
  - (v) about 2% by weight of sodium stearyl fumarate.
- 20. The pharmaceutical composition of claim 19, wherein said composition is in the form of a tablet.
- 21. The pharmaceutical composition according to claim 19, wherein said a pharmaceutically acceptable salt of 4-amino-1-hydroxybutylidene--1,1-

bisphosphonic acid is 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium salt trihydrate.

- 22. The pharmaceutical composition according to claim 19, wherein said a pharmaceutically acceptable salt of 4-amino-1-hydroxybutylidene--1,1-bisphosphonic acid is anhydrous 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium salt.
- 23. The pharmaceutical composition according to claim 16, comprising:
- (i) about 26% by weight of a pharmaceutically acceptable salt of 4-amino-1-hydroxybutylidene- 1,1-bisphosphonic acid;
  - (ii) about 32% by weight of mannitol;
  - (iii) about 40% by weight of microcrystalline cellulose;
  - (iv) about 1% by weight of croscarmellose sodium; and
  - (v) about 0.6% by weight of magnesium stearate.
- 24. The pharmaceutical composition of claim 23, wherein said composition is in the form of a tablet.
- 25. The pharmaceutical composition according to claim 23, wherein said a pharmaceutically acceptable salt of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid is 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium salt trihydrate.
- 26. The pharmaceutical composition according to claim 23, wherein said a pharmaceutically acceptable salt of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid is anhydrous 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid monosodium salt.

e ar an interest

- 27. A process for preparing a pharmaceutical composition suitable for oral administration to a human comprising:
- (i) forming a mixture of from about 0.5% to about 60% by weight of a pharmaceutically acceptable salt of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid, from about 10% to about 95% by weight of a non-reducing sugar selected from the group consisting of mannitol, xylitol, sorbitol, inositol, sucrose and trehalose, from about 2% to about 60% by weight of a binder selected from the group consisting of microcrystalline cellulose, hydroxypropyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose and polyvinylpyrrolidone; from about 0.5% to about 15% by weight of a disintegrant selected from the group consisting of starch, modified starch, croscarmellose sodium, crospovidone and sodium starch glycolate; and from about 0.1% to about 7% by weight of a lubricant selected from the group consisting of calcium stearate, magnesium stearate, stearic acid, talc, hydrogenated vegetable oil and sodium stearyl fumarate; and
  - (ii) compressing said mixture into a tablet.